Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Management

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 18310

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, TN 37208-3500, USA
Interests: inflammatory bowel disease; ulcerative colitis; Crohn's colitis; indeterminate colitis; endoscopic medicine; molecular diagnostics; biomarker; colonic ileal metaplasia; precision diagnostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our pleasure to invite investigators in the areas of clinical diagnostics and surgical management of inflammatory bowel disease (IBD) to submit their work for publication in this Special Issue of Medicina, an open access MDPI journal.

Predominantly colonic Inflammatory bowel disease (IBD) encompasses ulcerative colitis (UC), and Crohn’s colitis (CC), and when the diagnostic classification for these two diseases is inconclusive, the condition is termed indeterminate colitis (IC). Here, the central medical challenge is the discrimination of IBD into specific subtypes with high accuracy because it greatly effects the surgical care of patients. Diagnostic accuracy of IC into either UC or CC is of utmost importance when determining a patient’s candidacy for pouch surgery, restorative proctocolectomy (RPC), and ileal pouch–anal anastomosis (IPAA). Further, incorrect diagnosis and treatment carry potential morbidity from inappropriate and unnecessary surgery. Studies on RPC with IPAA for UC, IC, and CC functional outcomes are encouraged.

IBD is a significant public health challenge that afflicts millions, with continually increasing prevalence worldwide. Medically, IBD has no cure. It requires lifetime symptomatic treatment and generates a financial burden of up to USD 32 billion annually within the United States alone, with a therapeutics market over USD 16 billion globally and growing at a rate of 25% per year. Conservatively, traditional treatment protocols begin with pharmaceuticals, but adverse effects make them unsuitable for long-term use, and patients may become refractory to these agents, eventually requiring surgery to control the symptoms. Thus, current medical therapies remain suboptimal for IBD treatment, and there is a significant unmet need for new therapeutics that offer better long-term prognosis and improved risk/benefit profiles. The available cutting-edge research technologies in IBD have advanced our understanding of the disease, but there are still challenges regarding diagnosis and treatment outcomes. This Special Issue (SI) on “Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Management—Essential Material Needed” will present the acceptable surgical management advances and challenges in the treatment of patients suffering from IBD. This is to build a research community of authors and readers to discuss the latest research and develop new ideas and research directions on surgical treatment of IBD. Systematic analysis of authentic clinical surgery interaction is a crucial but limited element in improving quality care in IBD, and one which can be traced to the most pressing documented needs in IBD care. To make the case for the value of such work, in this SI, we provide an overview of the research on clinical surgery communication in the setting of IBD, situate that research within the existing health communication literature more generally, introduce programs of research on communication in IBD, and exemplify issues of interest emerging from the projects within programs.

Patients with medical refractory UC often undergo pouch surgery, RPC with IPAA. This intervention involves the removal of the entire colon and rectum while preserving bowel continuity, evacuation, continence/deferral, discrimination, and fertility. Long-term functional results are excellent. The challenge of diagnostic inaccuracy in colonic IBD is still a serious, unsolved problem and is associated with an increased risk of adverse outcomes, specifically CD that was not evident prior to colectomy and IC, which urgently need a solution. Recent findings in the areas of ectopic colonic ileal metaplasia and DEFA5 expansion, facilitating diagnosis of CC with accuracy, are very promising (PMID:33690604 and PMID:28817680).

Fibrostenosis, a hallmark of CD leading to stricture formation and bowel obstruction, remains a challenge in clinical management of IBD patients and represents a key event in the disease course, necessitating improved preventive strategies and multidisciplinary approach to diagnosis and management. The lack of antifibrotic therapies makes the elucidation of fibrosis mechanisms a priority, which could circumvent surgical resection. CD fibrotic strictures require endoscopic balloon dilatation and/or surgical resection. Surgical resection includes removing downstream blockage or constriction and keeping the upstream distended bowel to maintain lumina continuity, but recurrences after surgical resection are inevitable, and patients still suffer long-term bowel symptoms.

Dr. Amosy E M'Koma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • clinical diagnostics
  • colorectal surgery
  • Crohn’s colitis
  • ulcerative colitis

Related Special Issue

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 10364 KiB  
Article
Analysis of the Anti-Inflammatory Capacity of Bone Broth in a Murine Model of Ulcerative Colitis
by Laura M. Mar-Solís, Adolfo Soto-Domínguez, Luis E. Rodríguez-Tovar, Humberto Rodríguez-Rocha, Aracely García-García, Víctor E. Aguirre-Arzola, Diana E. Zamora-Ávila, Aime J. Garza-Arredondo and Uziel Castillo-Velázquez
Medicina 2021, 57(11), 1138; https://doi.org/10.3390/medicina57111138 - 20 Oct 2021
Cited by 4 | Viewed by 6920
Abstract
Background and Objectives: Nutritional deficiencies are one of the main triggers for the development of gastrointestinal diseases, such as ulcerative colitis (UC). Therefore, the objective of the present work consisted of determining the nutrients present in the bone broth (BB) and evaluating their [...] Read more.
Background and Objectives: Nutritional deficiencies are one of the main triggers for the development of gastrointestinal diseases, such as ulcerative colitis (UC). Therefore, the objective of the present work consisted of determining the nutrients present in the bone broth (BB) and evaluating their anti-inflammatory properties in a murine model of UC, induced by intrarectal administration of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS), and acetic acid (AcOH). The BB was prepared from the femur of bovine cattle and cooked in distilled water for 8 h at 100 ± 2 °C. Materials and Methods: The BB was administered ad libitum to BALB/c mice for 10 days before the induction of UC. Colon samples were collected for histological analysis and determination of cytokine expression levels by qPCR. Results: It was found that amino acids (AA) are the main nutritional contribution of BB, 54.56% of these correspond to essential AA. The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1β (61.12%), IL-6 (94.70%), and TNF-α (68.88%), and increased the expression of INF-γ (177.06%), IL-4 (541.36%), and IL-10 (531.97%). Conclusions: This study shows that BB has anti-inflammatory properties, and its consumption can decrease the symptoms of UC. Full article
Show Figures

Figure 1

11 pages, 513 KiB  
Article
A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy
by Mirko Di Ruscio, Gianluigi Lunardi, Dora Buonfrate, Federico Gobbi, Giulia Bertoli, Donatella Piccoli, Antonio Conti, Andrea Geccherle and Angela Variola
Medicina 2021, 57(10), 1048; https://doi.org/10.3390/medicina57101048 - 1 Oct 2021
Cited by 6 | Viewed by 1528
Abstract
Background and Objectives: Studies have shown a lower prevalence of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD), including amongst those receiving biological therapy. Aims were to determine the seroprevalence of anti-SARS-CoV-2 antibodies in IBD patients and to assess any association between [...] Read more.
Background and Objectives: Studies have shown a lower prevalence of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD), including amongst those receiving biological therapy. Aims were to determine the seroprevalence of anti-SARS-CoV-2 antibodies in IBD patients and to assess any association between seropositivity and IBD characteristics. Materials and Methods: Serum from adult IBD patients was prospectively collected between December 2020 and January 2021 and analyzed for anti-SARS-CoV-2 antibodies. Information about IBD characteristics and SARS-CoV-2 exposure risk factors was collected and analyzed. Serum from non-IBD healthcare workers formed the control group. Results: 311 IBD patients on biologics and 75 on mesalazine were enrolled. Ulcerative colitis (UC) extension (p < 0.001), Crohn’s disease (CD) phenotype (p = 0.009) and use of concomitant corticosteroids (p < 0.001) were significantly different between the two IBD groups. Overall seroprevalence among IBD patients was 10.4%. The control group showed a prevalence of 13.0%, not significantly different to that of IBD patients (p = 0.145). Only a close contact with SARS-CoV-2 positive individuals and the use of non-FFP2 masks were independently associated with a higher likelihood of seropositivity amongst IBD patients. Conclusion: In IBD patients, the prevalence of anti-SARS-CoV-2 antibodies is not determined by their ongoing treatment. Disease-related characteristics are not associated with a greater risk of antibody seropositivity. Full article
Show Figures

Figure 1

Review

Jump to: Research

13 pages, 1010 KiB  
Review
Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview
by Amosy Ephreim M’Koma
Medicina 2022, 58(5), 567; https://doi.org/10.3390/medicina58050567 - 21 Apr 2022
Cited by 17 | Viewed by 9037
Abstract
This article is an overview of guidelines for the clinical diagnosis and surgical treatment of predominantly colonic inflammatory bowel diseases (IBD). This overview describes the systematically and comprehensively multidisciplinary recommendations based on the updated principles of evidence-based literature to promote the adoption of [...] Read more.
This article is an overview of guidelines for the clinical diagnosis and surgical treatment of predominantly colonic inflammatory bowel diseases (IBD). This overview describes the systematically and comprehensively multidisciplinary recommendations based on the updated principles of evidence-based literature to promote the adoption of best surgical practices and research as well as patient and specialized healthcare provider education. Colonic IBD represents idiopathic, chronic, inflammatory disorders encompassing Crohn’s colitis (CC) and ulcerative colitis (UC), the two unsolved medical subtypes of this condition, which present similarity in their clinical and histopathological characteristics. The standard state-of-the-art classification diagnostic steps are disease evaluation and assessment according to the Montreal classification to enable explicit communication with professionals. The signs and symptoms on first presentation are mainly connected with the anatomical localization and severity of the disease and less with the resulting diagnosis “CC” or “UC”. This can clinically and histologically be non-definitive to interpret to establish criteria and is classified as indeterminate colitis (IC). Conservative surgical intervention varies depending on the disease phenotype and accessible avenues. The World Gastroenterology Organizations has, for this reason, recommended guidelines for clinical diagnosis and management. Surgical intervention is indicated when conservative treatment is ineffective (refractory), during intractable gastrointestinal hemorrhage, in obstructive gastrointestinal luminal stenosis (due to fibrotic scar tissue), or in the case of abscesses, peritonitis, or complicated fistula formation. The risk of colitis-associated colorectal cancer is realizable in IBD patients before and after restorative proctocolectomy with ileal pouch-anal anastomosis. Therefore, endoscopic surveillance strategies, aimed at the early detection of dysplasia, are recommended. During the COVID-19 pandemic, IBD patients continued to be admitted for IBD-related surgical interventions. Virtual and phone call follow-ups reinforcing the continuity of care are recommended. There is a need for special guidelines that explore solutions to the groundwork gap in terms of access limitations to IBD care in developing countries, and the irregular representation of socioeconomic stratification needs a strategic plan for how to address this serious emerging challenge in the global pandemic. Full article
Show Figures

Figure 1

Back to TopTop